The way phase 2 worked, as I understand it, is that everyone (n=46) was given VB-111 as a monotherapy. Then upon progression (median of 1 dose) they were put in 1 of the 2 cohorts: 1) Avastin alone or 2) Combo. Here's a link for review:
A total of 46 patients were enrolled in two sequential cohorts. In the first cohort, patients were treated with VB-111 as monotherapy for a median of only one dose and, upon disease progression, switched to Avastin (bevacizumab) alone as standard of care (Limited Exposure cohort). This cohort behaved like an Avastin historical control with a median Overall Survival (mOS) of 8 months.
In the second cohort, patients continued to receive treatment with VB-111 after progression, in combination with Avastin as the standard of care (Treatment Through Progression cohort). This cohort received in median 4 doses of VB-111, about 8 months of treatment.
News 
Market Data 
Discover 
